Randomized trial finds holding one preprocedure dose of a GLP-1 analog reduces residual gastric volume

The issue: GLP-1 analogs are being increasingly prescribed for weight loss and type 2 diabetes, but their gastric-slowing effects have raised concerns about residual gastric volume (RGV) and potential pulmonary aspiration during procedures requiring sedation.

Why this study matters: It compared residual gastric volumes (RGV) during endoscopy in patients who held one preprocedure GLP-1 analog dose to those who did not.

Primary care relevance: Primary care providers are often asked about holding medications before procedures. This study provides some objective evidence that holding GLP-1 analogs for a single dose before procedures reduces RGV.

Small study in overweight adults with and without diabetes showed improvement in MASH and fibrosis

The issue: MASH is a leading cause of liver disease with few pharmacologic options; SGLT2 inhibitors are being studied.

Why this study matters: It looks at the effects of SGLT2 inhibitors on MASH.

Primary care relevance: Dapagliflozin may have a role in MASH; larger trials are needed to confirm benefit and define indications.

FDA approves Cologuard Plus, designed to improve screening and reduce false positives

The issue: Cologuard is a popular stool-based screening test for colon cancer. However, it has a high false-positive rate.

Primary care relevance: Information on the accuracy of the next-generation Cologuard test.